Introduction {#Sec1}
============

Alcohol intoxication leads to metabolic and physiologic derangements that complicate the care of intoxicated trauma patients compared to their non-intoxicated counterparts \[[@CR1]\]. These physiologic changes include impaired cardiovascular function, blunting of catecholamine release leading to inadequate oxygen delivery to tissue and metabolic uncoupling, modulation of the innate immune system, and alterations in blood coagulation \[[@CR1]--[@CR8]\].

Acute and chronic alcohol consumption can have varying effects, and distinct, sometimes opposite, effects on coagulation following alcohol intoxication have been described in the literature. Some have described hypocoagulability in the intoxicated patient as evidenced by prolonged initiation of clot formation and decreased dynamics of clot formation resulting in a reduced risk of venous thrombotic events (VTE) in trauma \[[@CR3], [@CR4]\]. Conversely, others have established a link between alcohol intoxication and increased risk of thrombotic complications through elevated levels of plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of fibrinolysis \[[@CR2], [@CR9]\]. This differential risk of adverse effects appears to be related to the amount of and timing within which ethanol is consumed \[[@CR10], [@CR11]\]. While there is a decrease in fibrinogen and platelets reported with excess alcohol consumption \[[@CR12]\], there is also a reported increase in coagulation Factor VII, Factor VIII, and PAI-1 in the acutely intoxicated \[[@CR9], [@CR12], [@CR13]\]. On the other hand, Factor VII has been shown to decrease in chronic alcohol use, likely from liver disease and synthetic dysfunction \[[@CR14]\]. Furthermore, there is a greater increase in PAI-1 release compared to tissue plasminogen activator (tPA) in those who consume a larger amount of alcohol, thereby increasing the PAI-1:tPA ratio \[[@CR12]\].

Elevated levels of PAI-1 are associated with increased fibrinolysis shutdown, which is the most common fibrinolytic phenotype in the injured population and is associated with an increased mortality due to macro- and microthrombotic complications such as venous thrombotic events (VTE) and multiple organ failure (MOF) \[[@CR15]\]. Fibrinolysis shutdown has previously been identified as the most common fibrinolytic phenotype following injury and is also associated with increased mortality compared to physiologic fibrinolysis, often due to multiple organ failure \[[@CR15]--[@CR17]\] and has most commonly been measured by thrombelastography (TEG), a viscoelastic assay that provides a comprehensive assessment of clot formation and clot remodeling and degradation. Therefore, we hypothesize that alcohol intoxication is associated with an increased incidence of fibrinolysis shutdown on thrombelastography.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Our prospective Trauma Activation Protocol (TAP) registry includes all adult (≥ 18 years old) patients who met the criteria for the highest level of trauma team activation from 2014 to 2016 at the Ernest E Moore Shock Trauma Center at Denver Health (DHMC), Denver, CO, an American College of Surgeons verified and state-certified Level 1 trauma center. Exclusion criteria were unsalvageable injuries (defined by patients in asystole at emergency department arrival), isolated gunshot wounds to the head, pregnancy, documented chronic liver disease, or a known coagulation disorder. A rapid thrombelastogram (r-TEG) was run on whole blood from all of these patients under waiver of consent at the scene or immediately upon arrival less than 1 h postinjury. This clinical study was approved by the Colorado Multiple Institutional Review Board (COMIRB).

Clinical data were collected by trained research professional assistants (PRAs) and included demographic characteristics, injury severity, physiologic derangement, transfusions, and outcomes \[death, intensive care-free days (ICUFD), ventilator-free days (VFD)\]. Severe traumatic brain injury was defined as an Abbreviated Injury Scale (AIS) for Head ≥ 3. The New Injury Severity Score (NISS) measured injury severity. Massive transfusion was defined as greater than 10 units of red blood cells (RBC) or death within 6 h postinjury as we have found this definition to be related to adverse outcomes \[[@CR18], [@CR19]\]. Further, the inclusion of death within 6 h was to minimize survivor bias (i.e., non-survivors did not have the "opportunity" to receive transfusions) \[[@CR18], [@CR19]\]. The protocol for massive transfusion of blood products has been described previously and includes initial empiric blood component therapy (FFP:RBC in 1:2 ratio) \[[@CR20]\] followed by r-TEG-guided hemostatic resuscitation base on ACT \[s\], angle (°), maximum amplitude \[MA (mm)\], and lysis 30 min after MA (LY30 \[%\] \[[@CR21]\].

Blood samples from trauma patients {#Sec4}
----------------------------------

Samples were collected during trauma activations within 1 h of injury in the field or emergency department (ED) in tubes containing 3.2% citrate. All blood samples were obtained prior to administration of plasma or tranexamic acid (TXA). Determination of blood alcohol level (BAL) was requested at the attending physician's discretion. The lower limit of detection for BAL is 10 mg/dL (0.1 g/L).

Rapid TEG {#Sec5}
---------

A team of trained professional research assistants completed the viscoelastic assays. Citrated blood samples were analyzed using the TEG 5000 Thrombelastography Hemostasis Analyzer (Haemonetics, Niles, IL, USA) as previously described \[[@CR22]\]. The rapid TEG (activated by tissue factor and kaolin) was employed and the following indices were obtained from the tracings of the TEG: activated clotting time \[ACT (s)\], angle (°), maximum amplitude \[MA (mm)\], and lysis 30 min after MA \[LY30 (%)\]. Definitions for fibrinolysis phenotypes by rTEG were shutdown (≤ 0.9%), physiologic (\> 0.9--≤ 2.9%), and hyperfibrinolysis (≥ 3%) as previously described \[[@CR15]\].

Statistical analysis {#Sec6}
--------------------

SAS version 9.4 (SAS Institute, Inc. Cary, NC, USA) was used for statistical analysis. Non-normally distributed variables were expressed as median and interquartile range (IQR) and the Wilcoxon non-parametric test or the Kruskal--Wallis test was used for continuous variables. Normally distributed variables were presented as mean (standard deviation, SD). Fisher's exact test was used for categorical variables. The non-parametric Spearman Rho test was used for correlations. Receiver operator characteristic (ROC) curve analysis was done to determine the predictability of BAL to predict fibrinolysis phenotypes. Multinomial logistic regression models were used to assess the independent effect of BAL on the three lysis phenotypes. Model fit was assessed via deviance and the Pearson goodness of fit tests (higher *p* values reflect better fit). To minimize selection bias due to missing BAL, we conducted a sensitivity analysis including the patients without a measured BAL as an additional, separate category. All tests were two tailed with significance declared at *p* \< 0.05.

Results {#Sec7}
=======

Of 436 consecutive trauma activation patients enrolled between 2014 and 2016, 191 (43.8%) had blood alcohol levels (BAL) measured. Table [1](#Tab1){ref-type="table"} illustrates differences in patients that had a BAL measured and those that did not. Compared to patients for whom BALs was not obtained, those with BALs measured were more likely to have blunt trauma (68.1% vs 40.8%, *p* \< 0.001) and TBI (21.5% vs. 12.6%, *p* = 0.01), had increased incidence of isolated TBI (12.57% vs 6.12%, *p* = 0.02), had slightly, but significantly lower INR (1.2 (0.4) vs. 1.3 (0.5), *p* = 0.01), were less likely receive antifibrinolytics in the form of tranexamic acid (4.19% vs 9.39%, *p* = 0.36) and were less likely to undergo a massive transfusion (4.19% vs 20.82%, *p* \< 0.001). Other demographic and injury characteristics were similar. The median BAL was 150 mg/dL (1.5 g/L) (IQR: 0--251); therefore, we used this cutoff to define the high BAL group (\> 150 mg/dL or \> 1.5 g/L) versus low BAL (10--150 mg/dL or 0.1--1.5 g/L). The third category was undetectable BAL (\< 10 mg/dL or \< 0.1 g/L).Table 1Demographic characteristics of patients with and without ETOH measuredVariablesETOH not measuredETOH measured*p* valueMedianLower quartileUpper quartileMedianLower quartileUpper quartileAge31.825.8483426.147.40.443ED SBP11590139110901390.84ED HR10078120102801160.9ED GCS1591514415 \< 0.001ED temp (°C)36.636.336.936.536.236.80.017BMI26.423.930.626.123.529.70.41Blunt mechanism40.82%68.06% \< 0.001NISS22938176340.14Max AIS head and neck0020030.003Max AIS chest0030030.73Max AIS abdomen and pelvis0030020.11Max AIS extremities0030020.83Positive FAST25.59%13.79%0.001TBI12.65%21.47%0.014Isolated TBI6.12%12.57%0.014Massive transfusion20.82%4.19% \< .001Death17.57%31.15%0.027Lactate4.32.97.53.72.65.30.012Base deficit− 6− 10− 3− 7− 11− 40.65Platelet count257202.5309259.52053110.39INR1.111.31.111.30.021r-TEG ACT (s)1211131361211131280.022r-TEG angle (deg)71.664.575.470.96775.20.35r-TEG MA (mm)6255.56662.557.5660.3r-TEG LY30 (%)1.913.41.90.93.20.38Anti-fibrinolytics9.39%4.19%0.036Length of stay (LOS)61.51262130.2VFD26.517282623280.45ICUFD2415282520270.19Continuous variables are presented as median and interquartile range while categorical variables are presented as percentThe ^*\**^*χ*^2^ test was used for categorical variables and Wilcoxon test for continuous variables*BAL* blood alcohol level, *TBI* traumatic brain injury, *BMI* body mass index, *NISS* New Injury Severity Score, *ED* emergency department, *SBP* systolic blood pressure, *HR* heart rate, *GCS* Glasgow Coma Scale, *INR* International Normalized Ratio, *TEG* thrombelastography, *ACT* activated clotting time, *MA* maximum amplitude, *LY30* lysis 30 min after MA is achieved, *VFD* ventilator-free days, *ICUFD* intensive care unit-free days

Blood alcohol levels associated with clinical and laboratory risk factors {#Sec8}
-------------------------------------------------------------------------

Overall, 65 (34%) patients had no detectable BAL, 32 (16.8%) had BAL of 10--150 mg/dL (0.1--1.5 g/L), and 94 (49.2%) patients had BAL \> 150 mg/dL (\> 1.5 g/L). Characteristics of patients stratified by BAL categories are depicted in Table [2](#Tab2){ref-type="table"}. Patients with a high BAL had lower admission systolic blood pressure (SBP), increased base deficit (BD), and decreased LY30 (*p* \< 0.001 for all) (Table [1](#Tab1){ref-type="table"}). BAL had a moderate, but significant inverse linear correlation with LY30 (Rho = − 0.315, *p* \< 0.001), while there were no significant correlations between BAL and other TEG values (ACT, angle, MA) (Table [3](#Tab3){ref-type="table"}).Table 2Demographic characteristics by alcohol intoxication status and association with clinical and laboratory risk factorsVariablesBAL 0 mg/dLBAL \> 0--150 mg/dL or \> 0--1.5 g/LBAL \> 150 mg/dL*n* = 65*n* = 32*n* = 94*p* valueAge35.2 (25.6 to 47.9)29.5 (23.7 to 41.3)37.1 (28.6 to 47.3)0.085Male76.92%78.13%81.91%0.063ED SBP120 (102 to 140)100 (80 to 126)110 (90 to 138) \< 0.001ED HR103 (83 to 116)103 (78 to 112.5)100 (77 to 115)0.93ED GCS14 (4 to 15)15 (10 to 15)14 (3 to 15)0.11ED temp (°C)36.5 (36.3 to 36.8)36.6 (36 to 36.8)36.5 (36.1 to 36.8)0.67BMI26.1 (24.2 to 29.1)25.4 (21.8 to 29.3)26.2 (23.7 to 29.8)0.66Blunt mechanism67.69%56.25%72.34%0.44NISS19.5 (6 to 42.5)16.5 (8 to 27)17 (5 to 34)0.4Max AIS head and neck0 (0 to 3)0 (0 to 1.5)0.5 (0 to 3)0.24Max AIS chest1 (0 to 3)0 (0 to 3)1.5 (0 to 3)0.77Max AIS abdomen and pelvis0 (0 to 2)0 (0 to 2)0 (0 to 2)0.34Max AIS extremities0 (0 to 2)2 (0 to 3)0 (0 to 2)0.16Positive FAST18.03%7.41%12.79%0.46TBI21.54%15.6%323.40%0.27Isolated TBI12.31%9.38%13.38%0.74Massive transfusion6.15%6.25%2.13%0.72Death15.63%9.38%6.45%0.2Lactate3 (2.1 to 4.6)3.8 (2.7 to 5.5)4.1 (3 to 5.1)0.09Base deficit− 5 (− 8 to − 1)− 7.6 (− 11 to − 5)− 7 ( − 11 to − 5)0.001Platelet count268 (207 to 310)264 (216 to 332)252 (201 to 304)0.59INR1.1 (1 to 1.2)1.1 (1 to 1.3)1.1 (1 to 1.3)0.3RBC/24 h10.99%4.71%15.18%0.87r-TEG ACT (s)121 (113 to 128)121 (113 to 136)121 (113 to 128)0.25r-TEG angle (deg)72.7 (67.5 to 76.1)70.6 (66 to 74.7)70.6 (67 to 74.8)0.29r-TEG MA (mm)62.5 (58 to 67)63.3 (56.5 to 66.5)61.5 (56.5 to 65.5)0.36r-TEG LY30 (%)2.3 (1.3 to 3.7)2.2 (1.4 to 3.4)1.2 (0.6 to 2.7) \< 0.001Length of stay (LOS)5 (2 to 11)5.5 (1.5 to 13)7 (3 to 14)0.22VFD26 (22 to 28)27 (24.5 to 28)26 (23 to 28)0.85ICUFD24 (20 to 28)25 (21.5 to 28)25 (17 to 27)0.87Continuous variables are presented as median and interquartile range while categorical variables are presented as percentThe ^*\**^*χ*^2^ test was used for categorical variables and Kruskal--Wallis test for continuous variables*BAL* blood alcohol level, *TBI* traumatic brain injury, *BMI* body mass index, *NISS*New Injury Severity Score, *ED* emergency department *SBP* systolic blood pressure, *HR* heart rate, *GCS* Glasgow Coma Scale, *INR* International Normalized Ratio, *TEG* thrombelastography, *ACT* activated clotting time, *MA* maximum amplitude, *LY30* lysis 30 min after MA is achieved, *VFD* ventilator-free days, *ICUFD* intensive care unit-free daysTable 3Correlations with rapid TEG parameters and blood alcohol levelBALRho*p* valuerTEG ACT− 0.1190.10rTEG Angle− 0.0930.20rTEG MA− 0.1010.17rTEG LY30− 0.315 \< 0.001Inverse correlations between blood alcohol level and LY30 on rTEG were seen. Data are presented as Spearman correlation coefficient (Rho). Statistical significance is *p* \< 0.05*rTEG* rapid thrombelastography, *ACT* activated clotting time, *MA* maximum amplitude, *LY30* fibrinolysis 30 min after MA is achieved

Blood alcohol level and fibrinolysis phenotypes in injured patients {#Sec9}
-------------------------------------------------------------------

The distribution of fibrinolysis phenotypes varied significantly by BAL levels (Fig. [1](#Fig1){ref-type="fig"}, *p* = 0.009), with high BAL having more shutdown and less hyperfibrinolysis than the other two BAL groups.Fig. 1Blood alcohol level (BAL) and fibrinolysis phenotypes (*SD* fibrinolysis shutdown, *HYPER* hyperfibrinolysis, *PHY* physiologic). Patients with a high BAL class had an increased incidence of fibrinolysis compared to those with no detectable blood alcohol and those with \> 0--150 mg/dL (0--1.5 g/L)

Multinomial logistic regression for the three-category lysis-dependent variable (hyperfibrinolysis, shutdown, and physiologic serving as the reference group) showed that, after adjustment for age, blunt mechanism, NISS, admission GCS, and SBP, BAL levels \> 150 mg/dL (≫ 1.5 g/L) were independently associated with a threefold increase in the odds of shutdown compared to undetectable BAL (OR 3.37, 95% CI 1.04--8.05, *p* = 0.006). High BAL was also significantly associated with higher odds of shutdown compared to low BAL (OR 2.63, 95% CI 1.15--6.06) as shown in Table [4](#Tab4){ref-type="table"}. Low BAL was not significantly associated with abnormal lysis. Hyperfibrinolysis was not associated with either high or low BAL. A BAL \> 150 is an independent predictor of fibrinolysis shutdown (AUROC 0.76, 95% 0.68--0.85).Table 4Blood alcohol level effect on fibrinolysis phenotypeDependent variableBAL (mg/dL)Odds ratio95% confidence limits*p* valueHyperfibrinolysis \> 150 vs \< 100.5010.2141.1710.11 \> 150 vs 10--1500.8270.2972.3010.7210--150 vs \< 100.6060.2151.7080.34Shutdown \> 150 vs \< 103.0251.118.2440.03 \> 150 vs 10--1504.181.04716.6830.04310--150 vs \< 100.7240.1513.4640.69Multinomial logistic regression testing the independent effect of blood alcohol level (BAL) on a three-category outcome: hyperfibrinolysis (HYPER), fibrinolysis shutdown (SD) and physiologic fibrinolysis serving as the reference group. Odds ratios are adjusted for age, blunt mechanism, NISS, admission GCS and SBP. Deviance *p* = 0.674 and Pearson goodness-of-fit test *p* = 0.156 (higher *p* values indicate better goodness-of-fit)

In the sensitivity analysis, we added the patients for whom BAL was not obtained, adjusted for the same covariates as above. High BAL remained independently associated with shutdown compared to undetectable BAL (OR 2.93, 95% CI 1.12--7.67) and compared to untested patients (OR 2.05, 95% CI 1.07--3.93).

In binomial multiple logistic regression, high BAL did not independently affect mortality (*p* = 0.62), VFD \< 28 (*p* = 0.53), or ICUFD \< 25 days (*p* = 0.94), nor did it modify the association between fibrinolysis phenotype and these outcomes (*p* \> 0.05 for all interactions). We confirmed previous results that compared to physiologic fibrinolysis, both abnormal fibrinolysis phenotypes were associated with increased mortality (hyperfibrinolysis OR 2.27, 95% CI 1.13--4.58; shutdown OR 2.87, 95% CI 1.41--5.83) and VFD \< 28 (hyperfibrinolysis OR 1.95, 95% CI 1.20--3.17; shutdown OR 2.54, 95% CI 1.47--4.39). The number of patients with high BAL who died (*n* = 6) and the number of VTE in these patients (*n* = 2) were too small to allow reliable analyses within these subgroups.

Discussion {#Sec10}
==========

The distribution of fibrinolysis phenotypes in intoxicated trauma patients was shifted toward an increased prevalence of fibrinolysis shutdown compared to patients with no detectable alcohol. At the same time, this did not result in an increased risk of death. Previous studies have indicated a number of perturbations in viscoelastic-based measurements of blood clotting in an intoxicated and injured patient \[[@CR3], [@CR4]\]. Two previous studies have each shown that the time to clot formation and rate of clot propagation are impaired in intoxicated patients. Our study does not show significant increases in the time to clot formation as measured by the activated clotting time (ACT) in intoxicated patients or the rate of clot propagation. An explanation could be the type of activator used for the TEG assays. Both previous studies used kaolin-activated TEGs while our institution uses rapid TEGs, which are activated with tissue factor as well as kaolin.

Our results are consistent with findings in a recent study \[[@CR3]\] suggesting that major adverse outcomes (need for massive transfusion and death) are not significantly affected by acute alcohol intoxication. Howard et al. \[[@CR3]\] showed no difference in rates of transfusion and death in those who were intoxicated, specifically, the rates of death and massive transfusion are similar regardless of BAL class for each fibrinolysis phenotype. Overall, we found that patients who had BAL measured seemed slightly more likely to have TBI but had less bleeding/shock than those that were not tested for BAL. This could be explained by the fact that alcohol intoxication suppresses cognitive and motor function resulting in a lower GCS.

Several studies have investigated the potential role of alcohol consumption and thromboembolic risk. Spoerke et al. \[[@CR23]\] showed that both males and females had increased PAI-1, the inhibitor of tPA-mediated fibrinolysis, after consumption of alcohol. In the male population, this was also associated with a small decrease in LY30 (clot breakdown). In a study evaluating the effects of alcohol consumption on cardiac risk, Djousse et al. \[[@CR9]\] found that individuals who consumed larger amounts of alcohol, more than 14.9 g of alcohol per day (the equivalent of one drink), had increased circulating PAI-1, which they postulated increased the risk of thrombotic complications. Furthermore, evidence supports that in acute alcohol intoxication, there is an increase in both tPA and PAI-1 \[[@CR11], [@CR12]\]. However, the ratio of PAI-1:tPA is shifted to favor PAI-1 with the consumption of an increased amount of alcohol \[[@CR12]\]. Furthermore elevated triglyceride levels resulting from heavy alcohol consumption may further stimulate PAI-1 gene expression, especially in people with a genetic makeup particularly sensitive to PAI-1 \[[@CR24]\]. This increased PAI-1 gene expression could result in the inhibition of fibrinolysis and thus increase the risk for acute cardiac events \[[@CR24]\]. Interestingly, the type of alcohol consumed appears to effect the ratio of PAI-1:tPA. Tousoulis et al*.* investigated the effects of types of alcohol on the fibrinolytic system and discovered that acute alcohol consumption increased the PAI-1:tPA ratio; however, this effect was not observed after the consumption of red wine \[[@CR25]\]. These data support the notion that not only the amount of alcohol consumed but the type may adversely affect cardiovascular health.

In our study, a higher BAL (\> 150 mg/dL or \> 1.5 g/L) was associated with a lower LY30 on r-TEG suggesting increased resistance to tPA in this population. Furthermore, the odds of fibrinolysis shutdown were threefold higher if the BAL was \> 150 mg/dL (\> 1.5 g/L) and this BAL was also an independent predictor of fibrinolysis shutdown with an AUROC of 0.76, indicating BAL \> 150 mg/dL (\> 1.5 g/L) is a fair predictor of fibrinolysis shutdown. In vitro and in vivo studies have provided data that ethanol affects the fibrinolysis profile and studies in healthy human volunteers suggest that this decrease in fibrinolysis is secondary to circulating levels of PAI-1 \[[@CR2], [@CR26]\]. Our data are consistent with other previously published data that high levels of alcohol intoxication are associated with decreased fibrinolytic activity while low level of alcohol intoxication is not \[[@CR9]--[@CR12]\]. Furthermore, these data confirm that of Howard et al*.* who also recently evaluated alcohol effects on fibrinolysis using ROTEM \[[@CR27]\]. They similarly illustrated that elevated levels of ETOH resulted in decreased fibrinolysis by ROTEM \[[@CR27]\]. The confirmation of impaired fibrinolysis, on two similar but different viscoelastic platforms, in these two separate patient populations strengthens the notion that acute alcohol intoxication influences fibrinolytic phenotype more than previously thought and could be a risk factor for the development of fibrinolysis shutdown-related adverse outcomes.

Several studies have evaluated distinct fibrinolysis phenotypes, with fibrinolysis shutdown being associated with increased mortality and rates of organ failure \[[@CR15], [@CR17], [@CR28]\]. The CRASH-2 trial suggested that the early empiric use of tranexamic acid (TXA) reduces the rate of death in injured patients but identified increased mortality when this therapy was delivered \> 3 h after injury \[[@CR29]\]. Our group has argued that there should be a selective use of TXA in the injured patient as administration to those with a shutdown phenotype may be critical in the pathogenesis of postinjury organ failure and thrombotic complications \[[@CR30]\]. At our institution, TXA is administered to patients that are in hemorrhagic shock with evidence of hyperfibrinolysis on TEG as we have found that the use of TXA in those not in hyperfibrinolysis may increase the risk of postinjury organ failure, thrombotic complications, and mortality \[[@CR17], [@CR30]\]. Experimental data have revealed that ethanol-exposed animals show enhanced PAI-1 expression and pulmonary fibrin deposition with coincident exaggeration of pulmonary edema and inflammatory injury \[[@CR31]\]. High levels of alcohol and subsequent excess expression of PAI-1 may thus be a contributing factor toward the development of organ failure following injury and would likely be exacerbated with the concomitant use of antifibrinolytic therapy. Less than 10% of trauma activation patients received antifibrinolytic therapy overall, and less than 5% in patients that had a BAL measured making subgroup analysis of patients that received TXA unreliable.

However, while our data reveal increased odds of fibrinolysis shutdown in acutely intoxicated patients, there is an absence of increased mortality in this group as we would expect for those patients in fibrinolysis shutdown. This is also seen in other studies evaluating alcohol's effects on fibrinolysis \[[@CR27]\]. This could be due to an underpowered study to identify mortality differences. Furthermore, once the acute episode of intoxication resolves, the fibrinolytic phenotype could change from that of fibrinolysis shutdown to physiologic fibrinolysis or even hyperfibrinolysis. It may be that the patients who remain in a phenotype of fibrinolysis shutdown after the resolution of acute alcohol intoxication are the ones that have adverse effects in the form of late mortality or MOF.

Identifying patients with a high BAL would allow the stratification of patients into those with a higher risk of having fibrinolysis shutdown. Low fibrinolytic activity has been associated with an increased mortality following injury, with a mortality of 17--22% compared to a physiologic level of fibrinolysis of 3--14% \[[@CR15], [@CR28]\]. The cause of death in the shutdown cohort was typically late death as previously discussed, and more commonly associated with multiorgan failure \[[@CR15], [@CR28]\]. It has been a hypothesis that multiple organ failure is caused by microthrombotic complications stemming from the decreased clot breakdown associated with fibrinolysis shutdown \[[@CR15], [@CR28]\]. There are no pharmacologic interventions currently in use to specifically target fibrinolysis shutdown. However, by identifying alcohol intoxication as a modulator of the fibrinolysis phenotype, this could help guide future interventions to help reduce the incidence of fibrinolysis shutdown and subsequent micro- and macrothormbotic complications in the critically injured patient. Data suggest that an increased amount of PAI-1 and shifting the tPA:PAI-1 ratio in favor of PAI-1 is a likely factor that contributes toward increased incidence of fibrinolysis shutdown in the intoxicated patient.

The presented study has some limitations. These data reflect a single point in time of a dynamic process and does not take into account the temporal changes of the coagulation process and subsequent evolution of fibrinolysis phenotypes. Unfortunately, there were patients in our TAP protocol that could not be included in the study because no BAL was obtained. BAL was obtained at the discretion of the trauma team. This may have led to a selection bias that must be taken into consideration with the interpretation of these results. Furthermore, we did not have information on the amount or type of alcohol ingested, the time during which alcohol was consumed, and reliable data on chronic ingestion of alcohol, which may have diverse effects. There were very few patients within our analyzed cohort that had documentation of chronic alcoholism (*n* = 26, 13.6%). There was a statistically significant trend (M--H Chi-sq, *p* = 0.019) of high a BAL with documentation of chronic alcoholism, which may be due to increased frequency of documentation among BAL-positive patients. The significant association between BAL levels and LY30 was detected again among patients without documentation of chronic alcoholism (*p* = 0.007). However, the small number of patients with documented alcoholism limits the analysis in this group and, therefore, for the purpose of this study, we did not separate acute vs chronic users for analysis. We also acknowledge that a high BAL leading to increased risk of VTE is based on theory at this time as our cohort was not large enough to appropriately study this question.

In conclusion, in the injured patient, high BAL (\> 150 mg/dL or \> 1.5 g/L) is an independent predictor for fibrinolysis shutdown. The mechanism of alcohol-related shutdown remains to be elucidated however, data would suggest a shift in the PAI-1:tPA ratio favoring PAI-1 may be a major contributor. Postinjury fibrinolysis shutdown has been associated with increased risk of organ failure and thrombotic complications; thus, a high BAL may represent a risk factor for VTE and microthrombotic events. Furthermore, the use of anti-fibrinolytic agents in patients with high BAL may have adverse effects by precipitating a more profound resistance to fibrinolysis.
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